Drugs / AD-221B
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05131997 Comparator | Nov 2021 → Jun 2022 | hyperlipoproteinemia | Addpharma Inc. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD-221B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05131997 ↗ |